Products & Pipeline

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics through our proven drug discovery and development processes, our intellectual property portfolio and our regulatory and manufacturing expertise. GW’s research explores the potential therapeutic application of cannabinoids and we have evaluated the pharmacology of a number of cannabinoids across a wide range of disease areas.

Our primary focus is on disorders of the central nervous system (CNS) including epilepsy. Our lead cannabinoid product candidate is Epidiolex®, a liquid formulation of pure plant-derived cannabidiol, or CBD, which is in development for the treatment of a number of rare childhood-onset epilepsy disorders.

We commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States.

We have a deep pipeline of additional cannabinoid product candidates which include compounds in development for epilepsy, glioma and schizophrenia.

GW is in a unique position to develop and manufacture plant-derived cannabinoid formulations worldwide at sufficient quality, uniformity and scale for the purposes of pharmaceutical development and to meet international regulatory requirements.

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved


Dravet Syndrome
Lennox-Gastaut Syndrome
Tuberous Sclerosis
Phase 3

Sativex (U.S.)

Ms Spasticity
Phase 3

CBDV (GWP42006)

GWP42006 (CBDV)
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Completed Phase 1


GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Completed Phase 2
Completed Phase 2

Recent Pipeline News

Apr 18, 2018
London, UK, Carlsbad, CA, April 19, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary canna
Apr 12, 2018
- Long-Term Safety and Efficacy Data in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome to be Presented -